Gunderson Dettmer advised Sherlock Biosciences on the round
Sherlock Biosciences, an Engineering Biology company dedicated to making diagnostic testing better, faster, and more affordable, closed its Series A round, with a total investment of over $31 million from Northpond Ventures, Baidu Ventures, the Open Philanthropy Project, and other investors. The additional funds bring Sherlock’s total committed capital to $49 million, which includes a $17.5 million non-dilutive grant from the Open Philanthropy Project.
Sherlock launched in March to leverage the power of Engineering Biology tools, including CRISPR and Synthetic Biology, to create a new generation of molecular diagnostics that can rapidly deliver accurate and inexpensive results for a vast range of needs in virtually any setting. Potential applications include oncology, infectious disease, low-resource settings, agriculture, and at-home testing. The additional investors bring significant strategic value, as well as relevant experience in Deep Learning and Artificial Intelligence that will enhance Sherlock’s products and their impact on molecular diagnostics.
Gunderson Dettmer advised Sherlock Biosciences with a team including Tim Ehrlich (Picture), George Pothoulakis, Stephen Damato and Ruchir Patel.
Law Firms: Gunderson Dettmer;
Clients: Sherlock Biosciences, Inc.;